The results were similar in trial ATTRACTION-3, ESCORT and RATIONALE-302, monotherapy of ICI in second-line treatment of esophageal cancer demonstrated no meaningful improvement in OS compared with chemotherapy in patients with negative PD-L1 expression (25–27). The gene discussed is CD274; the disease is esophageal cancer.